- Previous Close
0.0250 - Open
0.0260 - Bid 0.0240 x --
- Ask 0.0290 x --
- Day's Range
0.0260 - 0.0260 - 52 Week Range
0.0130 - 0.0330 - Volume
13,536 - Avg. Volume
126,899 - Market Cap (intraday)
15.219M - Beta (5Y Monthly) -0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Jul 3, 2025 - Jul 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, Eastern Europe, the Middle East/North Africa, and internationally. The company offers the TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to Truscreen Group Limited in August 2020. TruScreen Group Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.
truscreen.comRecent News: TRU.AX
View MorePerformance Overview: TRU.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRU.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRU.AX
View MoreValuation Measures
Market Cap
15.16M
Enterprise Value
13.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.31
Price/Book (mrq)
7.63
Enterprise Value/Revenue
7.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-68.09%
Return on Assets (ttm)
-36.30%
Return on Equity (ttm)
-112.19%
Revenue (ttm)
2.68M
Net Income Avi to Common (ttm)
-1.83M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.74M
Total Debt/Equity (mrq)
18.25%
Levered Free Cash Flow (ttm)
-811.67k